There is one clinical trial.
The study aims to examine whether the combination of Lopinavir/Ritonavir plus Ribavirin for
treatment of severe acute respiratory syndrome (SARS) is superior to placebo.
Primary Outcomes
Measure: Development of severe SARS Time: Any time during the acute illness
Secondary Outcomes
Measure: Adverse events Time: Throughout the illness period
Measure: SARS-CoV Viral load Time: Throughout the illness period
Measure: Immunological profile Time: Throughout the illness period